1. Home
  2. PTHL vs IMRX Comparison

PTHL vs IMRX Comparison

Compare PTHL & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTHL
  • IMRX
  • Stock Information
  • Founded
  • PTHL 1998
  • IMRX 2008
  • Country
  • PTHL China
  • IMRX United States
  • Employees
  • PTHL N/A
  • IMRX N/A
  • Industry
  • PTHL
  • IMRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PTHL
  • IMRX Health Care
  • Exchange
  • PTHL Nasdaq
  • IMRX Nasdaq
  • Market Cap
  • PTHL 60.5M
  • IMRX 62.7M
  • IPO Year
  • PTHL 2024
  • IMRX 2021
  • Fundamental
  • Price
  • PTHL $3.84
  • IMRX $2.02
  • Analyst Decision
  • PTHL
  • IMRX Buy
  • Analyst Count
  • PTHL 0
  • IMRX 7
  • Target Price
  • PTHL N/A
  • IMRX $12.80
  • AVG Volume (30 Days)
  • PTHL 40.7K
  • IMRX 4.9M
  • Earning Date
  • PTHL 02-11-2025
  • IMRX 02-28-2025
  • Dividend Yield
  • PTHL N/A
  • IMRX N/A
  • EPS Growth
  • PTHL N/A
  • IMRX N/A
  • EPS
  • PTHL N/A
  • IMRX N/A
  • Revenue
  • PTHL $572,291.00
  • IMRX N/A
  • Revenue This Year
  • PTHL N/A
  • IMRX N/A
  • Revenue Next Year
  • PTHL N/A
  • IMRX N/A
  • P/E Ratio
  • PTHL N/A
  • IMRX N/A
  • Revenue Growth
  • PTHL 2.32
  • IMRX N/A
  • 52 Week Low
  • PTHL $3.32
  • IMRX $1.00
  • 52 Week High
  • PTHL $6.45
  • IMRX $7.68
  • Technical
  • Relative Strength Index (RSI)
  • PTHL N/A
  • IMRX 47.82
  • Support Level
  • PTHL N/A
  • IMRX $1.84
  • Resistance Level
  • PTHL N/A
  • IMRX $3.80
  • Average True Range (ATR)
  • PTHL 0.00
  • IMRX 0.29
  • MACD
  • PTHL 0.00
  • IMRX -0.03
  • Stochastic Oscillator
  • PTHL 0.00
  • IMRX 9.18

About PTHL Pheton Holdings Ltd Class A Ordinary Shares

Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: